Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.65 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.62 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.62 |
| ▸ | TNF | P01375 | 4/20 | 0.60 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.58 |
| ▸ | CIT | O14578 | 1/20 | 0.58 |
| ▸ | MUSK | O15146 | 1/20 | 0.58 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.58 |
| ▸ | STK10 | O94804 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | RAF1 | P04049 | 1/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.58 |
| ▸ | PRKCB | P05771 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6250129 | 0.94 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL4252948 | 0.90 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL10130045 | 0.88 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL6162405 | 0.88 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL6334316 | 0.86 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL30449051 | 0.86 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL6160279 | 0.86 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL4566793 | 0.85 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL30009966 | 0.85 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11TNF | |
| SCHEMBL4953393 | 0.84 | DDR2 (0.64) | MAPK14MAPK13MAPK12MAPK11TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | AMBIT BIOSCIENCES CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-7750160-B2 | Isoxazolyl urea derivatives as kinase modulators | AMBIT BIOSCIENCES CORPORATION (US) | 2010-07-06 | — | — | US | disclosed |
| EP-1232150-B1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7241758-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241758-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1408950-B1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1163236-B1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6765009-B2 | N-(5-TERT-BUTYL-3-(3-(4-((2-DIMETHYLAMINOMETHYL-PYRIDIN-4-YL) -PIPERAZIN-1-YL-METHYL) NAPHTHALEN-1-YL)UREIDO)-2-METHOXYPHENYL) METHANESULFONAMIDE FOR EXAMPLE; CYTOKINE INHIBITORS FOR TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-07-20 | — | — | US | disclosed |
| EP-1381592-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030125354-A1 | Compounds use as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | BOEHRINGER INTELHEIM PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| US-6492393-B1 | SUCH AS 1-(5-TERT-BUTYL-2-METHOXYPHENYL)-3-(4-(2-METHOXY-PYRIDIN-4YL-OXY)-NAPHTHALEN-1-YL)-UREA; CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6476023-B1 | Aromatic heterocyclic compounds as anti-inflammatory agents | BOEHRINGEN INGELHEIM PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| WO-2002083628-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1232150-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1163236-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6297381-B1 | INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR, UREAS OR THIOUREAS SUBSTITUTED BY A PYRROLE OR THIOPHENE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2001036403-A1 | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| WO-2000055152-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173917-A1 | UREA DERIVATIVES AS ABL MODULATORS | ABL1, ABL2, BCR | MAPK14 1436/4885MAPK13 1519/4885MAPK12 1372/4885 |
| US-20030125354-A1 | Compounds use as anti-inflammatory agents | EPX, MPO, RELA | MAPK14 3716/4885MAPK13 3680/4885MAPK12 2971/4885 |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | RELA, NFKBIA, NQO1 | MAPK14 3841/4885MAPK13 3871/4885MAPK12 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.